Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock.

Other equities analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, November 11th. Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th.

Coya Therapeutics Price Performance

COYA remained flat at $5.21 on Wednesday. The company had a trading volume of 48,589 shares, compared to its average volume of 71,649. Coya Therapeutics has a fifty-two week low of $4.75 and a fifty-two week high of $10.69. The stock’s 50 day moving average price is $7.00 and its two-hundred day moving average price is $6.65. The company has a market capitalization of $87.04 million, a PE ratio of -8.02 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.15. Sell-side analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.

Insider Activity at Coya Therapeutics

In other news, CEO Arun Swaminathan acquired 5,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were acquired at an average cost of $7.34 per share, with a total value of $36,700.00. Following the transaction, the chief executive officer now owns 5,000 shares in the company, valued at $36,700. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have purchased 9,510 shares of company stock worth $69,615 over the last 90 days. 12.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in COYA. GHP Investment Advisors Inc. purchased a new stake in Coya Therapeutics in the third quarter worth $169,000. Renaissance Technologies LLC purchased a new stake in shares of Coya Therapeutics in the 2nd quarter worth about $101,000. Gilbert & Cook Inc. bought a new position in shares of Coya Therapeutics in the 2nd quarter worth about $61,000. Finally, Geode Capital Management LLC lifted its position in Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after acquiring an additional 4,485 shares during the period. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.